Coya Therapeutics, Inc. Share Price & Technical Analysis
COYA · $4.71 (-2.08%)
Healthcare / Biotechnology
$4.71
-2.08%
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
12% return in May, -14% avg return in past 3 year May month.
-14% return in 2026, 13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -19% | 9% | -20% | 5% | 12% | – | – | – | – | – | – | – | -14% |
| 25 | 5% | 20% | -8% | 2% | -20% | 7% | 2% | 6% | -16% | 11% | 3% | -11% | 1% |
| 24 | -20% | 53% | 9% | -9% | -16% | -21% | 15% | -13% | 3% | 9% | -10% | -12% | -12% |
| 23 | -7% | -2% | -2% | 14% | -8% | -7% | -2% | -12% | 9% | 21% | 10% | 37% | 50% |
| 22 | – | – | – | – | – | – | – | – | – | – | – | -2% | -2% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$95.71M
P/E ratio
—
52W high
$7.75
52W low
$3.71
Volume
93,114
Beta
0.55
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Coya Therapeutics, Inc. share price today?
- Coya Therapeutics, Inc. (COYA) last traded around $4.71 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does COYA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for COYA. Download the app for real-time alerts.
- How can I analyze Coya Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.